NCT00704522View on ClinicalTrials.gov

Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

601

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Hepatitis C, ChronicHepacivirus
Interventions
BIOLOGICAL

Peginterferon alfa-2b (SCH 54031)

Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

DRUG

Ribavirin (SCH 18908)

Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.

BEHAVIORAL

Patient assistance program

"Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00704522 - Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) | Biotech Hunter | Biotech Hunter